Breast

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER2-Positive Breast Cancers

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024

A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.

A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)

Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)

A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016

A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042

Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337

A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE19-409

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146

A Phase II Study of Lonafarnib in Patients with Locally advanced and Metastatic Breast Cancer: Hoosier Oncology Group: BRE07-126

A Biological Sample Collection Protocol of Women With and Without Breast Cancer: Hoosier Oncology Group Study BRE06-120 for the Analytical Proteomics Team

A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group Study BRE06-109

A Phase II Study of Oral Enzastaurin in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane-Containing Regimen

A Phase I/II Study of PTK787 in Combination with Trastuzumab in Patients with Newly Diagnosed HER-2 Overexpressing Locally Recurrent or Metastatic Breast Cancer

A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients with Previously Treated HER-2 Positive Metastatic Breast Cancer

A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60

A Pilot Trial Incorporating ZD1839 (IRESSA®) into Adjuvant Therapy for Breast Cancer

Phase I/II Trial of Chronic Low Dose Epirubicin and SU5416 in Patients with Previously Untreated Metastatic Breast Cancer

Phase II Trial of Gemcitabine, Paclitaxel and Trastuzumab in Metastatic Breast Cancer: a Hoosier Oncology Group Trial

Combined anti-microtubule therapy: A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer, Hoosier Oncology Group BRE98-1

Randomized Pilot Trial of Combination Versus Sequential Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer

A Hoosier Oncology Group Phase II Study of Biweekly Cisplatin (C) and Paclitaxel (P) in the Treatment of Metastatic Breast Cancer: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial BRE94-1

A Phase II Study of Oral Etoposide and Ifosfamide in the Treatment of Patients with Stage IV Breast Cancer

A Phase III Study of Pre-Operative Chemotherapy, Cytoxan, Adria, 5-FU vs HD Adria, Cytoxan and G-CSF for Breast Cancer not Considered Candidates for Lumpectomy

Carboplatin and WR-2721 as First-Line Chemotherapy for Metastatic Breast Cancer (MBC): A Hoosier Oncology Group Study BRE89-1

A Retrospective Analysis of Proteomic, Genomic, and Pharmacogenetics in Patients Receiving Systemic Chemotherapy for Locally Advanced or Metastatic Breast Cancer

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study

Department of the Army, US Army Medical Research Acquisition Activity: Center of Excellence for Individualization of Therapy for Breast Cancer: Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study

Department of the Army, US Army Medical Research Acquisition Activity: Center of Excellence for Individualization of Therapy for Breast Cancer: Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study

Phase II Study of Methotrexate, Vinblastine Adriamycin and Cisplatin (M-VAC) Combination Chemotherapy for Previously Untreated or Minimally Treated Advanced Adenocarcinoma of the Breast